2. Academic Validation
  3. TRIM56 acts through the IQGAP1-CDC42 signaling axis to promote glioma cell migration and invasion

TRIM56 acts through the IQGAP1-CDC42 signaling axis to promote glioma cell migration and invasion

  • Cell Death Dis. 2023 Mar 4;14(3):178. doi: 10.1038/s41419-023-05702-6.
Qing Zhang # 1,  Jianglin Zheng # 1,  Wenjie Wu 1,  Haiyan Lian 2,  Natasha Iranzad 3,  Endi Wang 3,  Lianhe Yang 4,  Xuan Wang 5,  Xiaobing Jiang 6
Affiliations

Affiliations

  • 1 Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • 2 Department of Ophthalmology, Jili Hospital of Liuyang (Liuyang Eye Hospital), Changsha, 410300, China.
  • 3 Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.
  • 4 Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, 110013, Liaoning, China.
  • 5 Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. highprefer@126.com.
  • 6 Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. jiangxiaobing@hust.edu.cn.
  • # Contributed equally.
PMID: 36870986 DOI: 10.1038/s41419-023-05702-6
Abstract

Diffuse invasion is an important factor leading to treatment resistance and a poor prognosis in gliomas. Herein, we found that expression of the tripartite motif containing 56 (TRIM56), a RING-finger domain containing E3 ubiquitin Ligase, was markedly higher in glioma than in normal brain tissue, and was significantly correlated with malignant phenotypes and a poor prognosis. In vitro and in vivo experimental studies revealed that TRIM56 promoted the migration and invasion of glioma cells. Mechanistically, TRIM56 was transcriptionally regulated by SP1 and promoted the K48-K63-linked poly-ubiquitination transition of IQGAP1 at Lys-1230 by interacting with it, which in turn promoted CDC42 activation. This mechanism was confirmed to mediate glioma migration and invasion. In conclusion, our study provides insights into the mechanisms through which TRIM56 promotes glioma motility, i.e., by regulating IQGAP1 ubiquitination to promote CDC42 activation, which might be clinically targeted for the treatment of glioma.

Figures
Products
Inhibitors & Agonists
Other Products